NeurogesX, Inc. (NGSX)
$8.45
0.10 (+1.18%)
| CAPS Rating |
|
|---|---|
| Open | $8.71 |
| Previous Close | $8.45 |
| Daily Range | $8.29 - $8.95 |
| 52-Week Range | $0.89 - $9.20 |
| Market Cap | $149.09M |
| P/E Ratio | 0.24 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 130,032 |
| Average Daily Volume | 115,000 |
NGSX
VS S&P 500 (SPY)
How do you think NGSX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NGSX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NGSX News and Commentary
- US FDA approves NeurogesX Qutenza pain patch – Reuters
- 3 Companies Looking for Gratitude Early – The Motley Fool
Related News and Articles
- Now's a Great Time to Invest -- So Don't Blow It Like This – The Motley Fool
- This Stock Is a Train Wreck – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- The Hottest Sector for 2010 – The Motley Fool
- Abbott: Brave or Stupid? – The Motley Fool
- 5-Star Stocks Poised to Pop: American Oriental Bioengineering – The Motley Fool
- Do You Have the Guts to Buy? – The Motley Fool
- This Top Stock Is a Winner – The Motley Fool
- Amylin Scores a Hat Trick – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Finally Convinced? Benlysta Works! – The Motley Fool
- Winners and Losers of the House Health-Care Reform Bill – The Motley Fool
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- Small and Volatile, but Not for Long – The Motley Fool
- Saved by Emerging Markets. Sort Of. – The Motley Fool
RSS Headlines
Fool UK
